Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
7,253 total articles
Procter & Gamble is a high-quality consumer staple with durable free cash flow, a long dividend streak and valuation that looks reasonable relative to cash generation. We view PG as a buy for patient, income-oriented investors but recommend a defined entry, stop and target to manage macro and execution risk.
Apogee Therapeutics is a clinical-stage biotech with a lead anti-IL-13 program, zumilokibart (APG777), that has shown strong durability in Phase 2 and a runway extended by recent equity raises. The shares pulled back into the low $70s and look like a tactical long for patient traders willing to ride clinical catalysts into late 2026. This trade ide…
The Western Union Company (WU) trades at roughly $8.10 and yields about 11.5% from an annualized dividend of $0.94. With a market cap near $2.53B, free cash flow of $377.7M and EV/EBITDA of 4.9x, WU looks cheap relative to its cash generation. This trade idea lays out an entry, stop and target with catalysts and clear risk controls for a long-term …
TG Therapeutics is a tactical buy after management signaled a stronger 2026 outlook tied to BRIUMVI expansion and continued commercial execution. The company now sports a roughly $6.0 billion market cap, improving revenue traction, and still-constructive valuation metrics versus growth prospects. This trade lays out entry, stop, and target levels a…
Nebius reported a 684% revenue surge that has captivated traders. That growth looks real on the top line, but a thin liquidity profile, likely one-time drivers and opaque cash flow dynamics create a measurable downside if earnings quality or cash visibility disappoint. This is a tactical short idea with clearly defined entry, stop and targets over …
MercadoLibre (MELI) is under pressure as management sacrifices margins to defend Latin American market share and scale fintech products. Current weakness creates a tradeable long opportunity: enter near $1690, stop at $1525, target $2400 over a long-term window (180 trading days). Expect volatility in the next 10-45 trading days as investments read…
Microsoft ($MSFT) trades well above its 50-day average and at a premium to the market, but fundamentals remain solid: $3.16T market cap, $72.9B free cash flow, 30% ROE, and low leverage. For traders willing to accept limited valuation risk, a controlled long with a $426 entry, $400 stop and $455 target over a mid-term (45 trading days) horizon bala…
Gentherm trades at an enterprise value below $1.11B with EV/Sales ~0.72 and free cash flow of $78.6M despite winning $620M in new automotive awards and expanding into home/office wellness. Technicals show strength but some overbought signals; a disciplined entry and stop give a favorable risk/reward for a mid-term trade.
Dave Inc. looks like a fintech that has graduated from early-stage promise to near-term commercial clarity. With 2025 revenue up roughly 60%, net income of $195.9M, strong free cash flow of $326.5M, and a market cap near $3.4B, Dave is delivering both growth and profitability. This trade plan targets $420 over a 180-trading-day window while protect…
Kohl's ($KSS) delivered an earnings beat while management signaled no new store closures and a focus on omnichannel execution. The stock has recovered from its spring lows and now trades on single-digit earnings multiples with a 3.9% yield and positive technical momentum. We upgrade to a tactical long for a mid-term swing (45 trading days) with a c…
Netflix is sitting above a clean technical and fundamental floor after a painful selloff. The business is cash-generative, has strong returns on capital, and recent one-time items that distorted reported EPS are fading. With a market cap near $361B, EV/EBITDA of 9.5 and free cash flow of roughly $11.9B, the risk-reward favors a tactical long: entry…
Applied Digital's latest 15-year, $7.5B lease for 300 MW at Polaris Forge 3 creates a measurable demand gap that has the market re-rating the stock. Bullish trade: enter $49.00, stop $44.00, primary target $62.00 and secondary target $75.00 over a mid-term (45 trading days) horizon. Valuation is rich, but contracted revenue and hyperscaler appetite…
AMD is positioned to capture meaningful AI-related revenue growth through EPYC CPUs, GPU accelerators and differentiated system-level wins. We upgrade AMD to a buy and present a concrete trade plan calibrated to a 180-trading-day horizon that assumes continued data-center demand and margin improvement without needing AMD to displace Nvidia outright…
Ulta Beauty has pulled back from its 52‑week highs and is trading at a mid‑teens P/E with robust free cash flow and almost no financial leverage. That combination, plus improving technicals and an earnings calendar, sets up a defined-risk swing trade heading into the next report.
Fabrinet (FN) provides precision optical packaging and manufacturing that sits beneath the headlines of AI chips and cloud racks. At a current price of $660.66, the company trades at a premium multiple but brings 17% ROE, $201.7M in free cash flow, a clean balance sheet and a string of record revenues. I’m bullish on a mid-term swing into the next …
Netflix is trading near $86 and sits below several short-term moving averages, which has traders calling it a bear market. I disagree. With roughly $12 billion in free cash flow, a market cap around $360 billion, and operating returns that remain industry-leading, Netflix can re-rate as ad monetization and live-sports initiatives scale. This articl…
Crexendo is a small, capital-efficient cloud telecommunications and software business that has doubled off its 52-week low and is showing free cash flow generation, a clean balance sheet and a compact float. Those attributes support a high-conviction long trade targeting meaningful upside over 180 trading days, while acknowledging elevated valuatio…
HP reported a solid Q2 with revenue of $14.41B and EPS of $0.86, yet shares trade at just ~9.4x earnings and yield ~4.6%. Rising memory costs justify caution, but the company is a free-cash-flow generator ($2.88B last twelve months) with an enterprise value of ~$29.9B. This trade idea argues the risk/reward favors a mid-term long while treating the…
Eli Lilly is riding a powerful wave from its GLP-1 franchise and now appears to be extending its R&D muscle into infectious diseases while retatrutide posts another Phase 3 win. The combination of blockbuster sales momentum, a deep cash-generating business and new pipeline catalysts creates a buy-able setup on a disciplined pullback. Valuation is r…
Nano Labs is a microcap fabless semiconductor and AI-compute specialist that pivoted into crypto reserves while trimming opex. At $2.48 and a $57M market cap, the stock offers asymmetric upside if recent product and North American AI infrastructure initiatives gain traction. This is a high-risk, mid-term trade idea: enter at $2.48, stop $1.85, targ…
InMode (INMD) looks mispriced for a credible operational recovery. The company sits on a large cash position, generates meaningful free cash flow, and trades well below levels implied by strategic interest. I lay out a long trade with entry, stop and target geared to a multi-quarter turnaround through 2026 and into 2027.
Q32 Bio (QTTB) is a clinical-stage biotech focused on immune rebalancing through IL-7/TSLP receptor and complement programs. With a market cap near $200M, a lean balance sheet, and an upcoming mid-2026 data cadence tied to bempikibart advancement, we rate QTTB Buy. Our trade plan: enter at $11.81, stop $9.00, target $22.00 over a long-term horizon …
Celestica combines contract-manufacturing scale, recent outsized AI revenue growth, and a strategic AMD partnership that positions it as one of the purer public plays on rack-scale AI infrastructure. The shares trade with solid fundamentals but a demanding multiple. This trade idea lays out an entry at $355.72, a stop at $320.00 and a $420.00 targe…
Novo Nordisk (NVO) is pricing in persistent GLP-1 share loss and a protracted growth slowdown. Recent regulatory wins (CHMP recommendation for Wegovy 7.2 mg single-dose pen and an oral semaglutide approval recommendation) and still-healthy fundamentals argue for a tactical long. The trade targets a recovery toward $65 over the next 180 trading days…
Meta is no longer just a social-media advertiser. The company is re-rating into AI infrastructure, subscriptions and potentially cloud services. With a market cap near $1.60T, a 23x P/E and growing free cash flow, the stock offers asymmetric upside if AI monetization accelerates — but the path is capital-intensive and execution-dependent. This trad…
